STOCK TITAN

Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

TORONTO, ON / ACCESSWIRE / September 8, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference being held in New York, NY on September 12-14, 2022.

Edesa Presentation Details

Date: September 12, 2022
Time: 10:00 am Eastern Time
Presentation Slides: Available in the events section of the Edesa website.

Attendees who are interested in meeting with the company should contact their H.C. Wainwright representative or Edesa directly via email at investors@edesabiotech.com.

About Edesa Biotech, Inc.

Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that Edesa is developing as a treatment for Acute Respiratory Distress Syndrome (ARDS). Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. Sign up for news alerts. Connect with Edesa Biotech on Twitter and LinkedIn.

Contact

Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
investors@edesabiotech.com

SOURCE: Edesa Biotech



View source version on accesswire.com:
https://www.accesswire.com/715058/Edesa-Biotech-to-Present-at-Upcoming-HC-Wainwright-Investor-Conference

Edesa Biotech Inc

NASDAQ:EDSA

EDSA Rankings

EDSA Latest News

EDSA Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Biotechnology, Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing

About EDSA

founded in 2015, edesa biotech brings innovative new treatments for dermatological and anorectal diseases. late-stage prescription drugs developed by edesa biotech aim to help patients who experience limited treatment options. edesa biotech's focus on dermatology is led by an experienced team that have licensed global rights to clinical stage assets for dermatology and anorectal indications.